I agree. Also, people are still not talking about LaViv's application to acne scarring, burns, vocal cord scarring etc. These are all huge, unique markets. Getting approval "de-risks" this stock. I think a bigger, competing company may have some interest. They could easily buy FCSC for very little (little for them) and have the market cornered on wrinkles, acne scars etc.